What is liquid biopsy and how is it used for Colorectal Cancer

Understanding Liquid Biopsy for Colorectal Cancer

What Is a Liquid Biopsy?

A liquid biopsy is a blood test that detects cancer-related material circulating in your bloodstream. Instead of removing tissue (like a traditional biopsy), doctors take a simple blood sample and analyze it for signs of cancer.

Think of it this way: when cancer cells are present in your body, they release fragments of DNA and other molecules into your blood. A liquid biopsy captures and analyzes these "cancer signals" to provide information about your cancer without needing invasive procedures.

According to the BLOODPAC Consortium (Blood Profiling Atlas in Cancer), liquid biopsies can detect:

• Circulating tumor DNA (ctDNA) — fragments of cancer DNA floating in blood
• Circulating tumor cells (CTCs) — actual cancer cells in circulation
• Exosomes — tiny packages released by cancer cells containing DNA and RNA

---

How Liquid Biopsy Is Used for Colorectal Cancer

Liquid biopsies serve three main purposes in colorectal cancer care:

1. Early Detection & Screening

Several FDA-approved blood and stool tests can now detect colorectal cancer before symptoms appear:

Blood-Based Tests:

• Guardant Shield (FDA-approved July 2024) — detects colorectal cancer with 83% sensitivity and 90% specificity; NCCN-recommended for primary CRC screening
• Freenome CRC Blood Test — shows 79% sensitivity for detecting colorectal cancer and advanced adenomas (pending FDA approval)

Stool-Based Tests:

• ColoSense (FDA-approved May 2024) — uses stool RNA analysis with 93% sensitivity for colorectal cancer detection
• Cologuard Plus (FDA-approved October 2024) — stool DNA test with 94% sensitivity for Stage II and 97% for Stage III colorectal cancer

These tests are less invasive than colonoscopy and can be done at home, making screening more accessible.

2. Monitoring Treatment Response

After you start treatment, liquid biopsies can track whether your cancer is responding:

• Doctors monitor changes in ctDNA levels over time
• Decreasing ctDNA suggests your treatment is working
• Rising ctDNA may indicate the cancer is becoming resistant to current therapy
• This allows your oncologist to detect problems earlier than imaging alone

3. Detecting Minimal Residual Disease (MRD)

This is particularly important after surgery or initial treatment:

• Guardant LUNAR (research platform) — detects remaining cancer cells with 56-69% sensitivity in colorectal cancer patients
• If ctDNA is detected after treatment, it may suggest a higher risk of recurrence
• This information helps your doctor decide whether additional treatment is needed

---

Key Advantages of Liquid Biopsy for Colorectal Cancer

✅ Less invasive — simple blood draw instead of tissue biopsy
✅ Frequent monitoring — can be repeated easily without surgical risk
✅ Early warning system — may detect recurrence before imaging shows changes
✅ Comprehensive information — captures DNA from all tumor sites, not just one location
✅ Faster results — typically available within 1-2 weeks

---

Important Limitations to Understand

⚠️ Not a replacement for colonoscopy — While screening tests like Shield and ColoSense show promise, colonoscopy remains the gold standard because it allows doctors to remove precancerous polyps

⚠️ False positives and negatives — No test is 100% accurate. A positive result needs confirmation with imaging or other tests. A negative result doesn't guarantee absence of cancer.

⚠️ Lead time vs. benefit — Early detection doesn't always change outcomes. Finding cancer earlier is only beneficial if earlier treatment improves survival.

⚠️ Insurance coverage varies — Some tests are covered by Medicare, but coverage depends on your specific insurance and the test used.

---

Questions to Ask Your Colorectal Cancer Team

If you're interested in liquid biopsy testing, consider asking your oncologist:

1. "Is a liquid biopsy test appropriate for my specific stage and situation?"
2. "Which liquid biopsy test would you recommend, and why?"
3. "How will the results change my treatment plan?"
4. "How often would I need this test, and what does it cost?"
5. "Will my insurance cover this test?"
6. "What should I do if the test shows detectable ctDNA after treatment?"

---

Current Evidence & Resources

According to CancerPatientLab webinars on liquid biopsies, these tests are evolving rapidly. The BLOODPAC Consortium emphasizes that liquid biopsies work best when:

• Used alongside traditional imaging and tissue tests (not instead of them)
• Ordered by your oncologist as part of a comprehensive monitoring strategy
• Results are interpreted in the context of your complete clinical picture

For colorectal cancer specifically, the most established uses are:

• Screening (using Shield, ColoSense, or Cologuard Plus)
• Monitoring treatment response during active therapy
• Detecting recurrence after surgery or initial treatment

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.